Literature DB >> 21324800

Radiotherapy in rectal cancer: development, adequacy and radiotherapy utilisation rate. A comparative analysis with the most frequent tumour sites.

Sonia García Cabezas1, Amalia Palacios Eito, María Martínez Paredes, Eleonor Rivin del Campo.   

Abstract

INTRODUCTION: Radiotherapy is a basic weapon in the local treatment of multiple solid tumors. The radiotherapy activity has been evaluated in our centre during the past eleven years. The study focused on rectal cancer.
MATERIALS AND METHODS: This is a descriptive study of all radiotherapy procedures performed between January 1998 and December 2008. It quantifies the workload of each pathology treated, the rate of irradiation and its adequacy with optimal rates of irradiation according to the best available scientific evidence.
RESULTS: We quantified 9,622 external radiotherapy procedures of which 6,009 were associated with the five pathologies that involved the highest workloads. Of these, 905 were performed in rectal cancer. The workloads due to cancers of the breast, prostate, lung, gynaecological pathologies and rectal cancers were 23.2%, 11.8%, 11.6%, 6.3% and 9.3% respectively. The real "radiotherapy utilisation rates" of these pathologies were 62%, 20.2%, 34.3%, 21% and 64% respectively, while the "rates of adequacy" were 74.7%, 33.6%, 45.1%, 60% and 104.8%.
CONCLUSIONS: The "radiotherapy utilisation rate" for rectal cancer was equivalent to the estimated optimum rate as defined on the basis of reference groups. The therapy utilised developed chronologically in parallel with the available scientific evidence. The radiotherapy utilisation rates for breast and prostate cancer gradually increased, with a tendency to reach optimal rates. Radiotherapy as a treatment for lung cancer was underutilised. In global terms, the rate of utilisation of radiation therapy was low, although it displayed a tendency to increase.

Entities:  

Mesh:

Year:  2011        PMID: 21324800     DOI: 10.1007/s12094-011-0628-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  16 in total

1.  Preoperative radiotherapy for resectable rectal cancer: A meta-analysis.

Authors:  C Cammà; M Giunta; F Fiorica; L Pagliaro; A Craxì; M Cottone
Journal:  JAMA       Date:  2000 Aug 23-30       Impact factor: 56.272

2.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

3.  The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines.

Authors:  Geoff Delaney; Susannah Jacob; Carolyn Featherstone; Michael Barton
Journal:  Cancer       Date:  2005-09-15       Impact factor: 6.860

4.  The effect of overall treatment time on local control in patients with adenocarcinoma of the prostate treated with radiation therapy.

Authors:  R J Amdur; J T Parsons; L T Fitzgerald; R R Million
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-12       Impact factor: 7.038

5.  Radiation oncology: future needs and equipment. Current situation in Spain.

Authors:  Amalia Palacios Eito; María Espinosa Calvo; Ana Mañas Rueda; Manuel de Las Heras
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

6.  Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial.

Authors:  L Påhlman; B Glimelius
Journal:  Ann Surg       Date:  1990-02       Impact factor: 12.969

7.  Improved survival with preoperative radiotherapy in resectable rectal cancer.

Authors:  B Cedermark; M Dahlberg; B Glimelius; L Påhlman; L E Rutqvist; N Wilking
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

8.  Total mesorectal excision (TME) with or without preoperative radiotherapy in the treatment of primary rectal cancer. Prospective randomised trial with standard operative and histopathological techniques. Dutch ColoRectal Cancer Group.

Authors:  E Kapiteijn; E K Kranenbarg; W H Steup; C W Taat; H J Rutten; T Wiggers; J H van Krieken; J Hermans; J W Leer; C J van de Velde
Journal:  Eur J Surg       Date:  1999-05

9.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

Authors:  B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

10.  Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94.

Authors:  R Sauer; R Fietkau; C Wittekind; C Rödel; P Martus; W Hohenberger; J Tschmelitsch; H Sabitzer; J-H Karstens; H Becker; C Hess; R Raab
Journal:  Colorectal Dis       Date:  2003-09       Impact factor: 3.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.